1. Home
  2. INSG vs GANX Comparison

INSG vs GANX Comparison

Compare INSG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inseego Corp.

INSG

Inseego Corp.

HOLD

Current Price

$10.38

Market Cap

174.9M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.47

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INSG
GANX
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.9M
159.2M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
INSG
GANX
Price
$10.38
$2.47
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$15.50
$8.00
AVG Volume (30 Days)
181.8K
2.1M
Earning Date
02-18-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$165,876,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.24
$1.41
52 Week High
$18.11
$4.34

Technical Indicators

Market Signals
Indicator
INSG
GANX
Relative Strength Index (RSI) 42.05 38.79
Support Level $9.87 $2.30
Resistance Level $10.97 $3.29
Average True Range (ATR) 0.45 0.38
MACD 0.02 -0.12
Stochastic Oscillator 38.46 12.17

Price Performance

Historical Comparison
INSG
GANX

About INSG Inseego Corp.

Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: